Tower Research Capital (TRC)’s Aerie Pharmaceuticals AERI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-4,342
| Closed | -$66K | – | 6850 |
|
|
2022
Q3 | $66K | Buy |
4,342
+233
| +6% | +$2.71K | ﹤0.01% | 2917 |
|
|
2022
Q2 | $31K | Buy |
4,109
+3,609
| +722% | +$25.4K | ﹤0.01% | 3359 |
|
|
2022
Q1 | $5K | Sell |
500
-11,830
| -96% | -$91.2K | ﹤0.01% | 5160 |
|
|
2021
Q4 | $87K | Buy |
12,330
+9,230
| +298% | +$96.6K | ﹤0.01% | 2329 |
|
|
2021
Q3 | $35K | Sell |
3,100
-1,515
| -33% | -$22.1K | ﹤0.01% | 3256 |
|
|
2021
Q2 | $74K | Sell |
4,615
-1,280
| -22% | -$22K | ﹤0.01% | 2683 |
|
|
2021
Q1 | $105K | Buy |
5,895
+4,016
| +214% | +$69.4K | ﹤0.01% | 2552 |
|
|
2020
Q4 | $26K | Sell |
1,879
-2,089
| -53% | -$25.2K | ﹤0.01% | 3706 |
|
|
2020
Q3 | $47K | Sell |
3,968
-774
| -16% | -$9.43K | ﹤0.01% | 3565 |
|
|
2020
Q2 | $70K | Buy |
+4,742
| New | +$70.1K | ﹤0.01% | 2785 |
|
|
2020
Q1 | – | Sell |
-2,693
| Closed | -$65K | – | 4215 |
|
|
2019
Q4 | $65K | Buy |
2,693
+1,071
| +66% | +$22.2K | 0.01% | 1178 |
|
|
2019
Q3 | $31K | Buy |
1,622
+164
| +11% | +$3.76K | ﹤0.01% | 2175 |
|
|
2019
Q2 | $43K | Buy |
1,458
+1,398
| +2,330% | +$53.9K | ﹤0.01% | 1687 |
|
|
2019
Q1 | $3K | Buy |
+60
| New | +$2.64K | ﹤0.01% | 3343 |
|
|
2018
Q4 | – | Sell |
-339
| Closed | -$21K | – | 4540 |
|
|
2018
Q3 | $21K | Buy |
+339
| New | +$21.8K | ﹤0.01% | 2321 |
|
|
2018
Q2 | – | Sell |
-503
| Closed | -$27K | – | 4225 |
|
|
2018
Q1 | $27K | Buy |
503
+433
| +619% | +$24.2K | ﹤0.01% | 2025 |
|
|
2017
Q4 | $4K | Sell |
70
-4,581
| -98% | -$278K | ﹤0.01% | 3028 |
|
|
2017
Q3 | $226K | Buy |
4,651
+4,414
| +1,862% | +$241K | 0.02% | 684 |
|
|
2017
Q2 | $12K | Buy |
+237
| New | +$11K | ﹤0.01% | 1534 |
|
|
2016
Q2 | – | Sell |
-951
| Closed | -$12K | – | 5172 |
|
|
2016
Q1 | $12K | Buy |
+951
| New | +$15K | ﹤0.01% | 1798 |
|
|
2015
Q4 | – | Sell |
-3,461
| Closed | -$61K | – | 5239 |
|
|
2015
Q3 | $61K | Buy |
3,461
+2,471
| +250% | +$44.8K | 0.01% | 885 |
|
|
2015
Q2 | $17K | Buy |
990
+896
| +953% | +$16.4K | ﹤0.01% | 2260 |
|
|
2015
Q1 | $3K | Sell |
94
-1,079
| -92% | -$31.3K | ﹤0.01% | 3623 |
|
|
2014
Q4 | $34K | Buy |
+1,173
| New | +$29.7K | ﹤0.01% | 1261 |
|
|
2014
Q3 | – | Sell |
-2,080
| Closed | -$52K | – | 5028 |
|
|
2014
Q2 | $52K | Buy |
+2,080
| New | +$36K | 0.01% | 1271 |
|
|
2014
Q1 | – | Sell |
-1,409
| Closed | -$25K | – | 5094 |
|
|
2013
Q4 | $25K | Buy |
+1,409
| New | +$18.4K | ﹤0.01% | 2086 |
|
Tower Research Capital (TRC)'s AERI Position: Q4 2022 in Review
Tower Research Capital (TRC) sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 4,342 shares — an estimated $66K sold.
Tower Research Capital (TRC) first reported a position in AERI in Q4 2013 and held it in 26 quarters. The position peaked at $226K in Q3 2017. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.
- Tower Research Capital (TRC) reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
- Tower Research Capital (TRC) sold 4,342 Aerie Pharmaceuticals shares in Q4 2022, an estimated $66K.
- Tower Research Capital (TRC) first reported a position in Aerie Pharmaceuticals in Q4 2013 and held it in 26 quarters.
- Tower Research Capital (TRC)'s Aerie Pharmaceuticals position peaked at $226K in Q3 2017.
- 0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.
Based on Tower Research Capital (TRC)'s 13F filing for Q4 2022, filed 10 Feb 2023.